Evidence map›Paper›PMID 41226356›Full record

ArticleInternational journal of molecular sciences2025

Sex-Independent Upregulation of miR-146a-5p in Parkinson's Disease Patients: A Longitudinal Study.

Annamaria Vallelunga, Tommaso Iannitti, Giovanna Dati, Julio César Morales-Medina, Marina Picillo, Marianna Amboni, Calogero Edoardo Cicero, Roberto Cilia, Rosa De Micco, Anna De Rosa and 11 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Lack of Association BetweenInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Annamaria VallelungaCentro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, AP 62, Tlaxcala CP 90000, Mexico.
Tommaso IannittiSection of Experimental Medicine, Department of Medical Sciences, University of Ferrara, Via Fossato di Mortara 70, 44121 Ferrara, Italy.
Giovanna DatiDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, 84131 Salerno, Italy.
Julio César Morales-MedinaCentro de Investigación en Reproducción Animal, CINVESTAV-Universidad Autónoma de Tlaxcala, AP 62, Tlaxcala CP 90000, Mexico.
Marina PicilloDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, 84131 Salerno, Italy.
Marianna AmboniDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, 84131 Salerno, Italy.ORCID 0000-0002-6988-8197
Calogero Edoardo CiceroNeurologic Unit, AOU "Policlinico-San Marco", Department of Medical, Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, 95125 Catania, Italy.
Roberto CiliaParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy.
Rosa De MiccoDepartment of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy.
Anna De RosaDepartment of Neurosciences and Reproductive and Odontostomatological Sciences, Federico II University, 80131 Naples, Italy.
Alessio Di FonzoNeurology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0001-6478-026X
Roberto EleopraParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy.
Augusta GiglioDepartment of Neurosciences and Reproductive and Odontostomatological Sciences, Federico II University, 80131 Naples, Italy.
Giulia LazzeriCentro Parkinson e Parkinsonismi, ASST G. Pini-CTO, 20122 Milano, Italy.ORCID 0000-0002-9912-2002
Alessandra NicolettiNeurologic Unit, AOU "Policlinico-San Marco", Department of Medical, Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, 95125 Catania, Italy.
Claudio PacchettiParkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, 27100 Pavia, Italy.
Andrea SoricelliIRCCS SYNLAB SDN, 80143 Naples, Italy.ORCID 0000-0001-7011-7667
Alessandro TessitoreDepartment of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy.
Roberta ZangagliaParkinson's Disease and Movement Disorders Unit, IRCCS Mondino Foundation, 27100 Pavia, Italy.
Paolo BaroneDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, 84131 Salerno, Italy.
Maria Teresa PellecchiaDepartment of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Neuroscience Section, University of Salerno, 84131 Salerno, Italy.ORCID 0000-0002-6217-313X

Funding

Italian Medicines Agency AIFA code: 2016-02364714
6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. The absence of reliable fluid biomarkers continues to hinder early diagnosis and effective monitoring of disease progression. Circulating microRNAs (cmiRNAs) are potential candidates, given their stability in biofluids and their ability to mirror pathological processes. We conducted a longitudinal study in 30 early-stage levodopa-naive PD patients (22 men, 8 women). Serum samples were collected at baseline (T0) and at a follow-up time point two years later (T2). A panel of MicroRNAs (miRNAs) (miR-146a-5p, miR-34a-5p, miR-155-5p, miR-29a-3p, miR-106a-5p) were quantified by quantitative real-time PCR. Data were expressed as relative expression (2^-ΔCt), and statistical analyses included sex-stratified comparisons and paired tests for longitudinal changes. At baseline, no significant differences were found in the expression of the miRNAs between male and female PD patients. In contrast, longitudinal within-subject analysis revealed a highly significant upregulation in miR-146a-5p expression from T0 to T2 in both sexes (

Indexed as

MicroRNAsParkinson DiseaseAgedBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedSex FactorsUp-RegulationBiomarkersMicroRNAsMIRN146 microRNA, humanbiomarkersmiRNAsParkinson’s diseasepersonalized medicinesex and gendersex specific differencessex specific evidence

Identifiers

PMID41226356
PMCPMC12610492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.